Saturday 17 October 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS grew 82.0% and free cash flow fell 54.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow SXTP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.97 |
+8 more quarters Free account |
P/S ratio |
3.84 | 2.30 | 0.97 | 3.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.09) | (1.10) | (0.80) | (2.58) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.01 | 0.69 | (0.12) | 1.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.02 | 0.00 | |
EV/Operating CF |
(0.55) | (0.11) | 0.02 | (0.37) | |
EV/FCF |
(0.54) | (0.11) | 0.02 | (0.37) | |
Quick Ratio |
0.99 | 1.96 | 1.77 | 2.18 | |
Current Ratio |
2.32 | 3.34 | 2.66 | 2.87 | |
Net Debt/EBITDA |
0.47 | 1.65 | 1.68 | 1.82 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.21 | 0.25 | 0.19 | |
Operating CF/Net income |
0.99 | 1.31 | 1.37 | 0.91 | |
Capex/Depreciation |
(1.04) | (0.59) | (2.00) | (0.38) | |
Interest Coverage |
(1,622.21) | (1,496.43) | (550.97) | (1,367.94) | |
Research and Development Expense of Revenue |
287.97% | 173.66% | 219.25% | 153.20% | |
Selling, General and Administrative Expense of Revenue |
831.75% | 1,165.89% | 448.10% | 285.02% | |
Intangible Assets out of Total Assets |
0.07 | 0.04 | 0.04 | 0.02 | |
Share Based Compensation of Revenue |
22.61% | 49.04% | 21.46% | 6.60% | |
Graham Net Nets |
0.42 | 1.40 | 2.14 | 0.73 | |
Graham Number |
11.38 | 19.86 | 48.31 | 0.00 | |
Earnings Yield |
(123.32%) | (358.31%) | (553.22%) | 103.50% | |
Free Cash Flow Yield |
(194.03%) | (273.04%) | (519.60%) | (126.54%) | |
Revenue per Share |
0.08 | 0.09 | 0.47 | 0.58 | |
Operating CF per Share |
(0.84) | (1.59) | (2.53) | (2.30) | |
Capex per Share |
(0.03) | (0.02) | (0.20) | (0.03) | |
Free Cash Flow per Share |
(0.87) | (1.61) | (2.73) | (2.32) | |
Cash per Share |
0.39 | 1.93 | 4.11 | 4.48 | |
Shareholders Equity per Share |
0.95 | 2.75 | 5.04 | 4.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.95 | 2.75 | 5.04 | 4.73 | |
Free Cash Flow |
(2.32) | (2.78) | (1.83) | (2.13) | |
Working Capital |
2.13 | 4.38 | 3.05 | 4.11 | |
Capital Expenditures |
(0.09) | (0.04) | (0.14) | (0.03) | |
Net Current Asset Value |
1.98 | 4.24 | 2.91 | 3.97 | |
EV/EBIT |
0.00 | 0.00 | 0.02 | 0.00 | |
Capex to Sales |
0.41 | 0.26 | 0.43 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.43 | 0.41 | 0.50 | 0.50 | |
Average Payables |
1.06 | 1.32 | 1.23 | 1.03 | |
Average Inventory |
0.84 | 0.84 | 0.55 | 0.49 | |
Average Assets |
4.23 | 6.37 | 5.56 | 7.06 | |
Average Common Equity |
(7.13) | (5.18) | (5.90) | (4.41) |
Columns are period end dates